Duvelisib Capsules

Duvelisib (Copiktra) is a PI3K inhibitor that acts on two targets, PI3K-δ and PI3K-γ. It was approved by the FDA in September 2018 for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least two prior therapies. At the same time, the drug was also approved by the FDA for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) who have received at least two prior therapies.